Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
about
Preventing HIV infection: pre-exposure and postexposure prophylaxisRaltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.Overexpression of CDX2 in gastric cancer cells promotes the development of multidrug resistance
P2860
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
@ast
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
@en
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
@nl
type
label
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
@ast
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
@en
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
@nl
prefLabel
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
@ast
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
@en
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
@nl
P2093
P2860
P356
P1476
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells
@en
P2093
Lucia Palmisano
Maria Luisa Dupuis
Maurizio Cianfriglia
Stefano Vella
P2860
P2888
P356
10.1186/2050-6511-14-47
P577
2013-09-20T00:00:00Z
P5875
P6179
1049700126